SCHEMBL7211111

SCHEMBL7211111

CC12CCC(C)(CC1)c1cc(O)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
OPRM1 P35372 6/20 0.41
OPRD1 P41143 5/20 0.41
KDM4E B2RXH2 2/20 0.40
TP53 P04637 2/20 0.40
ALOX15 P16050 2/20 0.40
MTOR P42345 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
THPO P40225 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29911088 1.00 CYP3A4 (0.44) CYP3A4ALDH1A1LMNAESR1ESR2
SCHEMBL1360287 0.77 RXRA (0.49) CYP3A4ALDH1A1LMNATP53CYP1A2
SCHEMBL30701838 0.77 RXRA (0.49) CYP3A4ALDH1A1LMNATP53CYP1A2
SCHEMBL7106142 0.77 RARB (0.40) CYP3A4ALDH1A1LMNAESR1ESR2
SCHEMBL10899122 0.77 RARB (0.50) ESR1ESR2OPRM1OPRD1OPRK1
SCHEMBL7106913 0.75 RARB (0.42) CYP3A4ALDH1A1LMNAESR1ESR2
SCHEMBL11052113 0.75 CYP3A4 (0.43) CYP3A4ALDH1A1LMNAESR1ESR2
SCHEMBL11058779 0.75 CYP3A4 (0.43) CYP3A4ALDH1A1LMNAESR1ESR2
SCHEMBL11052109 0.75 CYP3A4 (0.43) CYP3A4ALDH1A1LMNAESR1ESR2
SCHEMBL11052108 0.75 CYP3A4 (0.43) CYP3A4ALDH1A1LMNAESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780856-B2 Compound and organic light-emitting device comprising same LG CHEM, LTD. (KR) 2023-10-10 US disclosed
US-11780856-B2 Compound and organic light-emitting device comprising same LG CHEM, LTD. (KR) 2023-10-10 US disclosed
WO-2004026810-A1 TRICYCLO[6.2.2]DODECA-2(7),3,5-TRIEN-4-CARBONYL)AMINO]-DERIVATIVES HAVING RAR-ALPHA- RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2004-04-01 WO disclosed
US-6620963-B1 Secondary carbocyclic amides, having preferential binding to retinoid acid receptors (RAR), used for prophylaxis of skin disorders and as topical microbiocides ALLERGAN, INC. 2003-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780856-B2 Compound and organic light-emitting device comprising same CRY1, CRY2, LEF1 CYP3A4 27/4885ALDH1A1 26/4885LMNA 2441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.